(Q43788963)

26 November 2017

title

The determination of AGE-peptides by flow injection assay, a practical marker of diabetic nephropathy (English)

1 reference

26 November 2017

Zilin S

1

1 reference

26 November 2017

Naifeng L

series ordinal

2

1 reference

26 November 2017

Bicheng L

series ordinal

3

1 reference

26 November 2017

Jiping W

series ordinal

4

1 reference

26 November 2017

language of work or name

1 reference

1 November 2001

1 reference

26 November 2017

1 reference

26 November 2017

volume

313

1 reference

26 November 2017

issue

1-2

1 reference

26 November 2017

page(s)

69-75

1 reference

Advanced protein glycosylation in diabetes and aging

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900651-9

Immunohistochemical detection of advanced glycosylation end products within the vascular lesions and glomeruli in diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900651-9

Histological localization of advanced glycosylation end products in the progression of diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900651-9

Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900651-9

Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900651-9

Recent progress in advanced glycation end products and diabetic complications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900651-9

The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900651-9

Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900651-9

Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900651-9

Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900651-9

Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900651-9

Advanced glycation end product (AGE): characterization of the products from the reaction between D-glucose and serum albumin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900651-9

The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900651-9

Comparison of advanced glycation endproducts on haemoglobin (Hb-AGE) and haemoglobin A1c for the assessment of diabetic control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2801%2900651-9

10.1016/S0009-8981(01)00651-9

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference